FACTOR VII OR VIIA GLA DOMAIN VARIANTS

(19)

(11)

EP 1 644 504 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.06.2010 Bulletin 2010/22

(45)	Mention of the grant of the patent:
	17.02.2010 Bulletin 2010/07

(21)	Application number: 04738925.9

(22)	Date of filing: 18.06.2004

(51)

International Patent Classification (IPC):

C12N 15/57^(2006.01)
C07K 14/745^(2006.01)

C12N 9/64^(2006.01)
A61K 38/36^(2006.01)

(86)	International application number:
	PCT/DK2004/000428

(87)	International publication number:
	WO 2004/111242 (23.12.2004 Gazette 2004/52)

(54)	FACTOR VII OR VIIA GLA DOMAIN VARIANTS VARIANTEN DER FAKTOR-VII- ODER -VIIA-GLA-DOMÄNE VARIANTS DU DOMAINE GLA DU FACTEUR VII OU VIIA

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL HR LT LV MK

(30)

Priority:

19.06.2003 US 479780 P
15.06.2004 DK 200400930

(43)	Date of publication of application:
	12.04.2006 Bulletin 2006/15

(73)	Proprietor: Bayer HealthCare LLC
	Tarrytown, NY 10591 (US)

(72)	Inventors:
	HAANING, Jesper, Mortensen DK-3460 Birkerod (DK) ANDERSEN, Kim, Vilbour DK-2700 Bronshoj (DK) BORNAES, Claus DK-2900 Hellerup (DK)

(74)	Representative: Burkert, Frank
	Bayer HealthCare AG Law and Patents 51368 Leverkusen 51368 Leverkusen (DE)

(56)

References cited: :

WO-A-00/66753
WO-A-99/20767

WO-A-01/58935
WO-A-2004/029091

SHAH A ET AL: "Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 8, 14 April 1998 (1998-04-14), pages 4229-4234, XP002092845 ISSN: 0027-8424
RUF WOLFRAM ET AL: "Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain" BIOCHEMISTRY, vol. 38, no. 7, 16 February 1999 (1999-02-16), pages 1957-1966, XP002297134 ISSN: 0006-2960 cited in the application
DATABASE EMBL 12 February 2004 (2004-02-12), XP002297135 Database accession no. ADF44983 & WO 03/093465 A (MAXYGEN HOLDINGS LTD; MAXYGEN APS ; ANDERSEN KIM VILBOUR (DK); HAANING) 13 November 2003 (2003-11-13)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).